PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTC Therapeutics, Inc.

PTC Therapeutics is a global biopharmaceutical company that delivers transformative therapies for people living with rare diseases, focusing on creating new therapies that address the underlying causes of diseases.

Metric
Company Name	PTC Therapeutics, Inc.
Symbol	PTCT
MSH ID	COM:PTCBIO
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	988
Website	ptcbio.com
LinkedIn
Founders

Metric
Market Cap	2.44B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	937.82M
Revenue (LTM)
Revenue (NTM)
Gross Profit	649.70M
EBITDA	-112.81M
Operating Income	-349.40M
Net Income	-626.60M
EPS	-8.37
Diluted EPS	-8.37
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.85
Operating Profit Margin	-0.22
EBITDA Margin	-0.12
Net Profit Margin	-0.53
Return on Equity	0.99
Return on Assets	-0.25
Return on Capital Employed	-0.15

COM:PTCBIO

PTC Therapeutics

Last Close

42.89

22/11 21:00

Market Cap

2.44B

Beta: -

Volume Today

548.74K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.94
P/B Ratio	-2.81
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.54
EV Multiple	-14.48

Metric
Days Sales Outstanding	75.78
Days Payables Outstanding	147.91
Days Inventory Outstanding	78.23
Operating Cycle	140.90
Cash Conversion Cycle	134.65
Asset Turnover	0.52

Metric
Operating Cash Flow	-158.42M
Free Cash Flow	-279.04M
Cash Flow to Debt	-0.11
Operating Cash Flow/Sales	-0.05
Free Cash Flow Yield	-0.18

Metric
Cash & Equivalents	594.00M
Accounts Receivable	-1.54M
Inventory	30.58M
Goodwill	82.34M
Debt to Capitalization	-0.44
Debt to Assets	0.56
Current Ratio	1.10
Quick Ratio	2.17

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.18
R&D to Revenue	0.92
SG&A to Revenue	0.10